iXensor Co., LTD. of Taipei at MEDICA 2020 in Düsseldorf -- COMPAMED Trade Fair
Manage stand orders
Select Option

iXensor Co., LTD.

6f., No.9, Aly. 2, Ln. 35, Jihu Rd., Nei Neihu Dist., 11492 Taipei
Taiwan
Telephone +886 2 87511335
Fax +886 2 87518059
info@ixensor.com

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

This company is co-exhibitor of
TAITRA Taiwan Excellence

Our products

Product category: Diagnostic rapid tests, Rapid tests in clinical chemistry, eHealth, telemedicine / telematics / telemetry

PixoTest® POCT system - Connected Care for Diabetes and Cardiovascular Disease Management

PixoTest® POCT System integrates multiple tests including HbA1c, Lipid (TC, TG, HDL, LDL) and data connectivity into one device, offering efficient and accurate results in 3 minutes. Since the launch in 2019, PixoTest POCT System has started to drive the digitalization of community care services in Europe and Africa.

All test data can be seamlessly uploaded to the PixoHealth cloud and connected to 3rd-party patient management systems. With easy integration of IVD and IT application, the PixoTest® POCT system can be perfectly installed in the pharmacy, clinics, community health centers, fitting into their daily operations to provide better efficiency and benefits brought by the connected POCT system.

More Less

Product category: Diagnostic rapid tests, Rapid tests in clinical chemistry, eHealth, telemedicine / telematics / telemetry

Eveline Ovulation Predictor Kit - World's First AI-powered OPK

Eveline is the world’s first AI-powered ovulation predictor kit (OPK) and aims to help families conceive stress-free in the new decade. Most couples take six months to a year to conceive, which usually includes complex calculations of ovulation cycles and hormone level measuring to determine the best timing. Eveline was created to help make this process simpler and smarter for couples.

Eveline’s Ovulation Predictor Kit (OPK) leverages the user's smartphone front camera to analyze ovulation test strips and uses the AI-powered Eveline app to accurately predict up to 7 fertile days per cycle. Users are conveniently reminded through personalized notifications when their fertility status reaches its peak, so that they never miss their perfect time to conceive.

With the newly introduced Eveline.Care service, the Eveline OPK even turns into a telehealth-enabled fertility monitoring system. 

Eveline.Care - Empower You to Consult Fertility Patients Better

Eveline.Care users authorize participating fertility professionals’ access to the fertility data they are recording in the Eveline App. Such data includes their luteinizing hormone (LH) levels, basal body temperature readings (BBT), mood, diet and daily symptoms.

The fertility professional can then remotely monitor the tracked data in real-time and provide personalized fertility advice to the patients through telehealth. In-person practice visits can thus be significantly reduced, resulting in time-savings and minimized exposure to potential viral infections like Covid-19.

Eveline.Care also enables fertility consultants to help women suffering from irregular periods and PCOS by facilitating the diagnosis through the precise LH level data that is recorded in the backend. This allows patients to manage their condition better and ultimately improve their chances of conceiving.

Eveline.Care comes at no additional cost for the patient. All that is required is having the Eveline OPK and a participating medical professional. Our service also safeguards the user’s privacy as the data shared with the fertility consultant can be withdrawn by the patient at any time.

More Less

Product category: Rapid tests in clinical chemistry, Diagnostic rapid tests, eHealth, telemedicine / telematics / telemetry

PixoTest® POCT COVID-19 Antigen Testing – fully digital pandemic management solution

The PixoTest® POCT COVID-19 Antigen Testing is a smart antigen testing solution designed as a new aid to managing the COVID-19 outbreak for corporations and healthcare facilities. 

PixoTest® COVID-19 Ag Test  – Research Use Only
The PixoTest® COVID-19 Ag Test is a rapid immunochromatographic assay for the qualitative detection of SARS-CoV-2 present in human nasopharynx. The PixoTest® COVID-19 Ag Test, together with PixoTest® POCT Analyzer (Model No. POC-X02), accommodates a wide range of workflows with its two test modes. In the Read Now mode, the analyzer yields test results within 30 seconds. The Walk Away mode offers automated timing and qualitative results in as short as 5 minutes for the positive results and up to 15 minutes for the negative cases.

PixoHealth Pass
The PixoHealth Pass app simultaneously displays test results issued by PixoTest® POCT Analyzer at “PixoHealth Pass-enabled” sites. Utilizing the PixoHealth Pass supports organizations and corporations worldwide to sustain business continuity.

More Less

Company news

Date

Topic

Download

Nov 11, 2020

iXensor gears up to launch the PixoTest® COVID-19 Antigen Test and PixoHealth Pass

  • PixoTest® is among the fastest COVID-19 antigen tests for smarter pandemic management, detecting positive SARS-CoV-2 infection in as short as five minutes.
  • The PixoTest® POCT Analyzer offers prompt, accurate, and objective results through the standardized analysis of the rapid tests.
  • PixoHealth Pass App is positioned as the digital screening tool to support health authorities, schools, event organizers, and employers in granting immediate access for negative cases.
TAIPEI, TAIWAN/DÜSSELDORF, GERMANY/PALO ALTO, USA – November 11th, 2020 – iXensor Co., Ltd. (6734.TWO)  iXensor, the pioneer of mobile health, aims to launch an entirely digitized rapid antigen testing solution in the winter of 2020. The PixoTest® COVID-19 Antigen Test, together with the PixoTest® POCT Analyzer, accommodates a wide range of workflows. It reveals positive results objectively in as short as 5 minutes and in 15 minutes for negative cases through computer-aided analysis. The affordability and timely testing features make it an accessible solution for effective COVID-19 screening in all near-patient settings.

PixoTest® COVID-19 Antigen Test serves to ease the overwhelming demand for screening by frontline health workers in the flu season, during which the rapid distinction between COVID-19 and influenza is critical for medical triage. Public health scholar Dr. Daniel B Larremore, addressed that “Effective surveillance, which encompasses the time to detect the first infection and to enforce outbreak control, depends heavily on the test frequency and the speed of reporting.”  

The laboratory validation studies have shown the detection limit of 0.5 ng/ml. iXensor will move into a clinical trial and plans to obtain CE mark approval this winter. The PixoHealth Pass app is designed to simultaneously display test results, which are issued by the PixoTest POCT Analyzer at “PixoHealth Pass-enabled” testing sites. The PixoHealth Pass carries encrypted test results, empowering users to access controlled public spaces, events, and international travel. Utilizing the PixoHealth Pass supports organizations and corporations to sustain business continuity. iXensor also develops the PixoHealth Pass Admin app for organizations such as schools to easily validate individual test results from the PixoTest analyzer with any authorized smartphone.

In addition to the PixoTest® POCT Analyzer, iXensor has prepared the mobile phone-based PixoTest® COVID-19 Antigen Test in the pipeline as the scalable solution. The PixoTest® Mobile Analyzer is running on iXensor’s machine learning-enabled PixoTech®, possessing an immense scalability in addressing massive outbreaks. 


Media Contact
Spokesperson: Patrick Liao
Company Website: www.ixensor.com
Email: pr@ixensor.com
Phone: +886-2-8751-1335 ext.205

More Less

Oct 30, 2020

Eveline.Care enables telehealth supported fertility consulting to help women conceive safely amid the ongoing pandemic and fertility crisis


Global fertility rates are dropping at alarming rates and the ongoing Covid-19 pandemic is making the situation even worse. Estimates for the US alone assume that up to 500’000 babies won’t be born in 2021 because of it. More than a third of women delay or entirely avoid having babies now due health concerns and economic uncertainty. As a consequence of this baby bust, many countries will face shrinking populations, eventually leading to societies with inverted age structures that threaten social security systems.

Despite the grim economic outlook, there remains a significant number of women who are trying to conceive, but are not able to because of infertility issues. According to the CDC, over 13% of women aged 15-49 in the USA suffer from impaired fertility.

Secondary infertility, the inability to have a second baby, is another often overlooked issue. While 2% of American women are experiencing hardship with primary fertility, the rate for secondary infertility is more than double that and reaches a terrifying 20% in some parts of Europe.

How Eveline.Care can help
Eveline.Care combines Eveline’s Ovulation Predictor Kit (OPK) with a back-end system that enables fertility professionals to seamlessly access their patients' recorded ovulation test data. This allows doctors to remotely monitor a patient’s fertility condition and provide comprehensive consultation to help women conceive faster from the safety of their homes.

Eveline’s OPK leverages the user's smartphone front camera to analyze ovulation test strips and then uses the AI-powered Eveline app to accurately predict up to 7 fertile days per cycle. Users are conveniently reminded through personalized notifications when their fertility status reaches its peak, so that they never miss the perfect time to conceive.

But that’s not all. With the newly introduced Eveline.Care service, the Eveline OPK turns into a telehealth-enabled fertility monitoring system.

How does Eveline.Care work?
Eveline users authorize participating fertility professionals of their choice access to the fertility data they are recording in the Eveline App. Such data includes their luteinizing hormone (LH) levels, basal body temperature readings (BBT), mood, diet and daily symptoms.

The fertility professional can then remotely monitor the tracked data in real-time and provide personalized fertility advice to the patients through telehealth. In-person practice visits can thus be significantly reduced, resulting in time-savings and minimized exposure to potential viral infections like Covid-19.

Eveline.Care also enables fertility consultants to help women suffering from irregular periods and PCOS by facilitating the diagnosis through the precise LH level data that is recorded in the backend. This allows patients to manage their condition better and ultimately improve their chances of conceiving.

How Eveline.Care facilitates IUI 
Another use case of Eveline.Care lies in supporting Intrauterine Insemination (IUI) treatments. For a successful IUI procedure, the right timing is crucial. Latter can either be determined by an ultrasound monitoring of the follicular growth or by detecting the LH surge through urinary testing.  

According to recent research, both methods offer similar effectiveness in terms of achieved pregnancy rates. However, the LH surge detection method that is enabled by Eveline.Care allows for more convenience for the patient as it can be done conveniently from the comfort of her home. 

Once the LH surge happens, the participating doctor is automatically notified through the Eveline.Care backend and then invites the patient to visit for the IUI procedure.This reduces the risk that the patient misses her appointment and can increase the chance of a successful IUI treatment. 

Eveline.Care comes at no additional cost for the patient. All that is required is having the Eveline OPK and a participating medical professional. Our service also safeguards the user’s privacy as the data shared with the fertility consultant can be withdrawn by the patient at any time.

Media Contact 
Contact Person: Nicola Krapf
Eveline website: www.evelinecare.com
Company website: www.ixensor.com
Email: pr@ixensor.com
Phone: +1 888-673-1085

More Less

Sep 14, 2020

Healthtech startup iXensor accelerates the adoption of telemedicine in community pharmacies amid COVID-19 pandemic

  • PixoTest® POCT Analyzer digitalizes the chronic disease management service at hundreds of community pharmacies in Italy.
  • Prompt, accurate, and portable mobile diagnostics increase the convenience of regular monitoring for severely impacted diabetes and hypertension patients amid pandemic.
  • The effortless data management capability of point-of-care testing enables the sizable adoption of digital healthcare services.

TAIPEI, TAIWAN – September 14, 2020 – iXensor Co., Ltd. (6734.TWO)  iXensor, the pioneer of mobile health, enhances medical diagnostics' accessibility in community care and home care with its innovation of PixoTest® POCT System. Over the past few months, patients who need to see doctors regularly suffered from the de-prioritization of clinical visits due to the COVID-19 outbreak. Several studies revealed that diabetes is the most adversely affected area among chronic diseases.

iXensor swiftly formulates the digitalized community care model with its PixoTest® POCT System, which integrates digital patient management features and point-of-care tests into one solution, enabling pharmacy chains to introduce the service of HbA1c and lipid panel check-up via a digital membership program. When a member patient walks into any one of the pharmacies for a regular HbA1c and lipid panel test, their GPs can access test results over the digital platform and make data-driven treatment plans promptly. The new service has been rolled out to around 500 pharmacies in Italy.

Severe impacts on patients of diabetes and hypertension

A recent study on the Impact of COVID-19 on routine care for chronic diseases, (published in the clinical journal of Diabetes and Metabolic Syndrome), revealed first-hand insights of the global survey completed by healthcare professionals from 47 countries worldwide. Diabetes was the most impacted chronic disease by the reduction in healthcare resources, followed by chronic obstructive pulmonary disease, hypertension and heart disease. More than half of the respondents (67%) rated moderate or severe effects on their patients due to changes in healthcare services since the outbreak. As the pandemic continues, experiencing delay in routine care and treatment may potentially lead to severe consequences.

Community pharmacies’ value amplified via digitized service for chronic disease management

“Health systems are reimagining how they will effectively manage chronic diseases in a COVID-19 era when the status quo of serial in-person visits to brick-and-mortar health care facilities will no longer be feasible2.” addressed by Dr. Jacob B. Mirsky from Massachusetts General Hospital and Harvard Medical School

While health systems are finding the balance for managing the COVID-19 pandemic, health tech companies seize the trend and look to accelerating pharmacy chains' role in primary care. Mr. Oronzo Cervelli - The CEO of Alpha Pharma, which connects mobile diagnostics, pharmacy chains, and a digital patient care platform, commented that "We always try to enhance the value of modern medical and IT technology for our pharmacy clients. Adopting PixoTest® POCT System helps us to empower pharmacy customers to practice telemedicine. It allows healthcare professionals to incorporate POCT practice into the existing workflow easily and efficiently manage patient testing records."

PixoTest® POCT System's data connectivity competency played a critical role in revamping the community pharmacies' service model in Italy. "We anticipate that more chronic disease patients will soon benefit from health tech solutions through the trend of digital transformation in the pharmacy sector, especially in the unprecedented time of the COVID-19 outbreak", said Dr. Carson Chen, CEO of iXensor.


Media Contact
Contact Person: Theresa Yang
PixoTest website: www.pixotest.com
Company website: www.ixensor.com
Email: pr@ixensor.com

More Less

May 18, 2020

iXensor tackles COVID-19 with two testing solutions in the pipeline

 
On February 21st, 2020, iXensor formed the COMBAT project team to tackle the global COVID-19 pandemic challenge from the testing and digital solution perspective, aiming to aid the early detection of COVID-19 infections. Two state-of-the-art antigen-based testing solutions are in the development stage.

Our team has been working relentlessly hard on both sides of the Pacific Ocean with 15 hours time difference to strategize solutions aggressively.  Building on top of our strength in integrating medical engineering, biochemistry, and information technology, we are developing an innovative molecular diagnostic solution that carries iXensor’s DNA for being highly mobile and close to the patients. In this case, the target patients will be COVID-19 suspects, so authorities and employers can test, track, and isolate them accordingly.

Up to this point in time, we have two cutting-edge antigen-based testing solutions for both big-scale screening and precision diagnosing use cases in the development stage. We are looking forward to announcing our answers to this pandemic to the public soon and supporting the safe “Back to work” return of the global economy.

More Less

About us

Company details

iXensor, founded in 2012, is the pioneer of mobile health. iXensor turns smartphones into lab-grade mobile medical diagnostics. In 2017, iXensor introduced the PixoTest® Blood Glucose Monitoring System as the world’s first US FDA approved smartphone camera-based blood test.

Based on the core PixoTech® platform, iXensor has ventured into both at-home self-testing and professional clinical diagnostics across infectious diseases, women’s health, chronic diseases and cardiovascular diseases.

Our vision is to make quality healthcare accessible and timely by driving the paradigm shift of point-of-care testing with the highly scalable PixoTech® platform.

More Less

Company data

Number of employees

20-49

Area of business
  • Electromedical equipment / Medical Technology
  • Diagnostics

Company information as a PDF file